{"entity":{"id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","aka":["PETRANHA"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT05367440 as active not recruiting, last updated 2026-08-26. Enrolment is 174 actual participants. Interventions: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide. Primary measures include Number of patients with Adverse Events and Serious Adverse Events; Part A: Number of patients with Dose Limiting Toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05367440","url":"https://clinicaltrials.gov/study/NCT05367440"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib","enzalutamide","abiraterone","darolutamide","apalutamide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05367440","phase":"1/2","setting":"A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05367440","source":"https://clinicaltrials.gov/study/NCT05367440","fetchedAt":"2026-10-07T16:53:41.225Z","studySha256":"5b1b5176be547c9c79ed4c8311cfb5614f4d05d3279b560454cf2c6c3c95ec89","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-26","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":174,"enrolmentType":"ACTUAL","siteCount":20,"recruitingSiteCount":0,"countries":["Australia","Italy","United Kingdom","United States"]}],"started":"2022-06-02","startedType":"actual","enrolled":174,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05367440/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}